Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CARTER-WALLACE’s NDA FOR BUTIBEL SEDATIVE IS UNDER REVIEW BY FDA

Executive Summary

CARTER-WALLACE's NDA FOR BUTIBEL SEDATIVE IS UNDER REVIEW BY FDA, which apparently is considering withdrawing the antispasmodic sedative's approval in connection with its DESI product status. "The company is awaiting a reply from the FDA concerning its request for hearing on Butibel," Carter-Wallace says in its recently-released 1992 annual report. The company markets the combination product (belladonna extract and butabarbital sodium) in elixir and tablet forms. FDA already has proposed withdrawing Carter-Wallace's NDA for the combination tranquilizer product Deprol (meprobamate and benactyzine) under DESI. An Administrative Law Judge ruled that the Deprol NDA should be withdrawn, Carter-Wallace said; the company has appealed the decision to FDA Commissioner Kessler. Both Butibel and Deprol remain on the market, a spokesperson said. FDA's Pulmonary-Allergy Drugs Advisory Committee recommended in March that Carter-Wallace's mucolytic expectorant Organidin (iodinated glycerol) should remain on the market pending FDA review of efficacy data to determine benefit versus potential carcinogenicity ("The Pink Sheet" March 30, p. 5). Carter-Wallace "is developing additional data in support of the safety and efficacy of the [Organidin] products and has implemented" the committee's other recommendations, the annual report states. "Withdrawal of the DESI products subject to review would not require material write-offs and would not have a material adverse effect on sales or earnings," the annual report says. "Any substantial reduction in Organidin sales or the discontinuance of marketing of the Organidin products as a result of regulatory action would not require material write-offs and would not have a material adverse effect on the Company's financial position, but in the absence of related reductions in marketing and other operating expenses, would have a material adverse effect on earnings," the report notes.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel